No abstract available.
Minocycline

No abstract available.
Darier Disease* ; Minocycline* ; Tetracycline

No abstract available.
Darier Disease* ; Friction* ; Keratosis* ; Minocycline

The results of intraprostatic injection of fosfomycin were compared to those of oral minocycline therapy in patients with nonbacterial prostatitis. Nonbacterial prostatitis did not recur in 26 out of 33 patients with fosfomycin injected into the prostate and in 16 out of 48 patients treated with oral minocycline. Non-recurrence rate within each group was compared as 78.8 per cent to 33.3 per cent, respectively, demonstrating that intraprostatic fosfomycin treatment was more successful than oral minocycline therapy. The pain and discomfort experienced by the patients during direct injection into the prostate was minimal. Hematuria was always practically present after the injection. Intraprostatic fosfomycin injection is believed to be new alternative method in the treatment of nonbacterial prostatitis.
Fosfomycin* ; Hematuria ; Humans ; Minocycline* ; Prostate ; Prostatitis*

No abstract available.
Methicillin Resistance* ; Methicillin-Resistant Staphylococcus aureus* ; Minocycline*

Despite the high prevalence of benign hepatic cysts, they rarely exhibit symptoms. Radiologic studies such as ultrasonography or computed tomography disclose these cysts incidentally. Occasionally, large cysts may compress organs next to them, resulting in accompanying symptoms in patients. Recently, some reports have shown that treatment with minocycline chloride instillation into the cyst, after aspiration of cystic fluid, produces good results. First, we instilled doxycycline into the cyst after aspiration of the cyst with a resultant decrease in size. We aspirated 25% of the cyst followed by instillation of minocycline chloride (200 mg in 10 ml of 2% lidocaine) into the recurrent cyst which became larger 45 days later. In the other case we succeeded in making the cyst decrease in 4 months with no recurrence by an instillation of minocycline chloride (500 mg in 10 ml of 2% lidocaine) following aspiration of 25% of the cyst. We report, with references, both cases in which we have succeeded.
Doxycycline ; Humans ; Minocycline* ; Prevalence ; Recurrence ; Ultrasonography

BACKGROUND: Confluent and reticulate papillomatosis(CRP) of Gougerot and Carteaud is an uncommon disorder of unknown cause for which a variety of treatments have been proposed. OBJECTIVE: We attempted to evaluate the therapeutic effect of oral minocycline for CRP. METHOD: Nine patients(age range, 14 to 38; mean age, 21years) with CRP were included in this study. They took minocycline 100mg daily. The therapeutic effect was evaluated weekly by 5 scoring systems according to the percentage clearing of the skin lesion: poor (score 1), <25% clearing; fair (score 2), 26-50%; good (score 3), 51-75%; excellent (score 4), 76-95%, clear(score 5), >95%. RESULTS: Two out of 9 patients showed complete clearing(score 5) of the skin lesions within 2 weeks. Seven patients revealed incomplete clearing(score 4) within 3 to 8 weeks. The mean scoring for 9 CRP patients was 4.2. Recurrences were noted in two patients at 24 and 26 months, respectively, but they responded to re-treatment with minocycline. The patients did not show any adverse reactions apart from two patients who developed mild pruritus. CONCLUSION: We recommend minocycline as the first choice of treatment for CRP because minocycline is safe, economic and effective.
Humans ; Minocycline* ; Papilloma* ; Pruritus ; Recurrence ; Skin

Digital mucous cysts are observed frequently on the lateral or dorsal aspect of the digital fingers. Digital mucous cysts are prone to recur after simple excision, electrocoagulation, intralesional injection of corticosteroid and a variety of other therapeutic maneuvers. In this report, we describe one patient with digital mucous cyst who was successfully treated with intralesional injection of 1 mg/ml of minocycline hydrochloride without any sequelae.
Electrocoagulation ; Fingers ; Humans ; Injections, Intralesional ; Minocycline ; Sclerotherapy

OBJECTIVES: We studied the efficacy and safety of repeated aspiration therapy and minocycline sclerotherapy for cystic thyroid nodules in the euthyroid patients and the factors which might appear to influence the outcome of therapy. SUBJECT AND METHODS: 114 patients with predominantly cystic thyroid nodules were studied. All of the patients underwent the first aspiration therapy, and patients with recurrent cystic lesions after the first aspiration treatment underwent repeated aspiration therapy or additive minocycline sclerotherapy. The patients were followed up ultrasonically 1 and 3 months, and every three month thereafter after the treatments. RESULTS: In 106 patients of 114 patients, cumulative success rate of the treatments was 54.6%. Cumulative success rate of only aspiration treatments(n=81) was 45.1%. 83 patients of 114 patients was recurred after the first aspiration therapy. In these patients, Cumulative success rate of repeated aspiration treatments(n=58) was 24.1%, Cumulative success rate of additive minocycline sclerotherapy(n=25) was 88.0%. Treatment modalities and longest diameter of the lesions significantly influenced the outcome of the trea tments. The effect of the larger longest diameter of cystic thyroid nodule would tend to reduce the cummulative success rate, and the cutoff point of the longest diameter was 4.5 cm. There were no significant adverse effects except for transient pain around the injection site in 12 patients (46%). Cytologic study showed 4 (3.5%) of 114 patients to be malignant. CONCLUSION: Minocycline sclerotherapy of cystic thyroid nodules is a useful and tolerable non-operative therapeutic method in patients with recurrent cystic thyroid nodules after repeated aspiration therapy. The size of a cystic thyroid nodule influence the outcome of aspiration therapy but may not inflcence the outcome of minocycline sclerotherapy.
Humans ; Minocycline* ; Sclerotherapy ; Thyroid Gland* ; Thyroid Nodule*

BACKGROUND: Pharmacoeconomic analysis is increasingly becoming an integral component of the overall profile of new drugs. Since its introduction in 1981, isotretinoin (13-cis-retinoic acid) has revolutionized the treatment of severe cystic acne by dramatically improving clinical outcomes. Isotretinoin has also been used to treat less-than-severe forms of acne, particularly patients who failed in conventional therapy. PBJECTIVE: This study was undertaken to evaluate the cost-effectiveness of isotretinoin and minocycline for acne treatment. METHOD: We analyzed cost of drug, medical management of the disease and any adverse reactions, average total cost and cure rate (%), cumulative reduction rates (%) of grade, recurrence rate (%), total cost to final cumulative reduction rates (%) of grade and relative cost effectiveness ratio for each drug on the basis of total cost per disease-free period, RESULTS: 1. Total costs of isotretinoin and minocycline group were 795, 354.5+/-87, 382.6won and 432, 271.5+/-3, 892.1won, respectively (p<0.05). 2. Adverse rates of isotretinoin and minocycline group were 88.2% and 25.8%, respectively (p<0.05). 3. Disease free period of isotretinoin and minocycline group were 7.12+/-.51 months and 3.15+/-.62 months, respectively (p<0.05). 4. Rates of cure of isotretinoin and minocycline group were 29/34 (85.3%) and 20/31 (64.5%), respectively (p<0.05). 5. Rates of relapse of isotretinoin and minocycline group were 7/29 (24.1%) and 10/20, respectively (50.0%) (p<0.05). 6. The final cumulative reduction rates of grade of isotretinoin and minocycline group were 96.3+/-4.5% and 65.6+/-2, 6%, respectively (p<0.05). 7. Total costs to of final cumulative reduction rate (%) of grade of treatment between isotretinoin and minocycline group were 5, 331.2+/-24.5won and 5, 986.2+/-02.1won, respectively (p>0.05). 8. Total costs to disease-free period between isotretinoin and minocycline group were 82, 342.7+/-41.2won and 135, 782.3+/-32.3won, respectively (p<0.05). 9. Cost effectiveness ratio of isotretinoin on total costs to disease-free months was 0.65. CONCLUSION: This study has observed better cost-effectiveness of isotretinoin in acne patients in terms of disease-free periods, possibility of cure, rates of relapse, total costs to disease-free period in spite of its higher cost than minocycline.
Acne Vulgaris* ; Cost-Benefit Analysis ; Humans ; Isotretinoin* ; Minocycline* ; Recurrence